Is BPC-157 Legal in Ohio?

The Short Answer: A Federal Gray Zone, Not an Ohio-Specific Ban

BPC-157 is not illegal to possess in Ohio in the way that a Schedule I controlled substance is illegal. No Ohio statute names BPC-157 by compound or class. The legal constraints on BPC-157 are federal, rooted in FDA drug approval law and compounding pharmacy regulations, and those federal rules effectively block any legitimate clinical dispensing pathway in the state.

Understanding exactly why requires separating three distinct legal questions: (1) Is BPC-157 an approved drug? (2) Can compounding pharmacies make it? (3) Can a person legally possess it?

What BPC-157 Actually Is

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a partial sequence of human gastric juice protein BPC. Its amino acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Preclinical animal studies have examined its effects on wound healing, tendon repair, and gastrointestinal protection, with a 2018 review in the journal Current Pharmaceutical Design identifying multiple organ-protective effects in rodent models [1]. No phase III randomized controlled trial in humans has been completed or published as of this article's review date.

No FDA-Approved Drug Application Exists

The FDA has approved zero drug products containing BPC-157 [2]. That single fact is the foundation of every downstream legal question. Without approval, BPC-157 cannot be marketed, prescribed, or dispensed as a drug through ordinary pharmacy channels in any U.S. State, Ohio included.

Federal Compounding Law and the 503A/503B Framework

Compounding pharmacies operate under a different legal track than standard drug manufacturers. Section 503A and Section 503B of the Federal Food, Drug, and Cosmetic Act allow pharmacies to prepare certain non-approved drug substances, but only under strict conditions defined by the FDA [3].

The 503A Bulk Substances List

Under 503A, a compounding pharmacy serving individual patients may use a bulk drug substance only if: (a) the substance appears on an FDA-nominated and evaluated list, (b) it is a component of an FDA-approved drug, or (c) the substance has a USP or NF monograph. BPC-157 meets none of those three criteria.

The FDA maintains a public list of nominated 503A bulk substances categorized as Category 1 (under consideration for inclusion), Category 2 (under review with identified concerns), or Category 3 (nominated but insufficient information). BPC-157 sits in the Category 2 bucket, meaning the FDA has identified concerns that must be resolved before it could ever appear on an affirmative list [4]. A Category 2 placement is effectively a hold, not a green light.

The 503B Outsourcing Facility Rules

Section 503B outsourcing facilities, which produce sterile compounded drugs in larger batches for healthcare providers, face an even narrower permitted list. The FDA publishes a separate 503B bulk substances list. BPC-157 does not appear on it [5]. Outsourcing facilities that compound BPC-157 for patient use would be operating outside their federal authorization.

What This Means in Practice for Ohio Pharmacies

Ohio compounding pharmacies are licensed and regulated by the Ohio State Board of Pharmacy under Ohio Revised Code Chapter 4729. The Board requires compliance with all applicable federal law, including FDA compounding regulations [6]. A licensed Ohio pharmacy that compounded BPC-157 for patient dispensing could face Board sanctions, federal regulatory action, or both. No Ohio exemption or state-level carve-out exists to override the federal framework.

Is BPC-157 a Controlled Substance in Ohio?

No. The DEA schedules controlled substances under 21 U.S.C. 812 [7]. BPC-157 does not appear in Schedules I through V at the federal level. Ohio's controlled substance schedules, maintained under Ohio Revised Code Chapter 3719, mirror and extend the federal schedules but do not independently list BPC-157 [8].

This distinction matters practically. Possessing a Schedule I substance like heroin without authorization is a criminal offense. Possessing BPC-157 purchased from an overseas or domestic research chemical vendor is not, by itself, a state or federal criminal act for an individual. The legal exposure falls on sellers making drug-sale claims, not typically on individual buyers.

The Analog Act Does Not Apply

The Federal Analogue Act (21 U.S.C. 813) treats certain Schedule I analogs as controlled substances when intended for human consumption [9]. BPC-157 is a peptide, not a small-molecule phenethylamine or tryptamine analog. It does not meet the structural or pharmacological similarity criteria that bring a compound under the Analogue Act. Ohio has its own analog provisions under ORC 3719.013, which similarly do not capture peptide compounds like BPC-157.

The Research Chemical Market: Legal to Buy, Risky to Use

Domestic and international vendors sell BPC-157 openly as a "research chemical" or "for laboratory research only." The legal rationale is straightforward: selling a compound for legitimate research purposes, with no drug claims, does not trigger FDA new drug approval requirements in the same way.

What "Research Use Only" Actually Means

The label "research use only" (RUO) is a regulatory designation. Under 21 CFR 809.30 and FDA guidance, RUO products are intended for in-vitro diagnostic development and basic research, not for administration to humans [10]. Vendors who sell BPC-157 as RUO while implicitly or explicitly marketing it for human self-injection may be violating FDA rules, but the agency's enforcement has historically focused on large-scale operations rather than individual purchasers.

Quality and Safety Risks Are Real

Without FDA oversight, there is no mandatory testing for sterility, pyrogens, heavy metals, or accurate peptide concentration. A 2020 analysis published in the journal Drug Testing and Analysis found that 43 of 44 peptide products purchased from online research chemical vendors contained measurable impurities or incorrect concentrations [11]. Injecting a contaminated, unsterile peptide carries risks of systemic infection, abscess, and immune reactions.

No Legitimate Telehealth Prescription Path Exists

Some telehealth platforms market "BPC-157 prescriptions." Because no FDA-approved BPC-157 product exists and compounding pharmacies cannot legally dispense it, any such offering operates outside the legal framework. The FDA's Office of Compliance has issued warning letters to compounders promoting unapproved peptides [12]. Ohio residents should treat any telehealth offer of a compounded BPC-157 prescription with significant skepticism.

How Federal Enforcement Has Treated Peptides

In October 2023, the FDA finalized its decision to remove several peptides from the 503A bulks list and placed others under heightened review. The agency's stated reasoning centered on lack of clinical efficacy data, safety signals from animal studies, and the risk of misuse when dispensed outside the normal drug approval process [13].

The FDA's position, stated in its 2023 bulk substances guidance, reads: "A drug substance may not be used in compounding under section 503A of the FD&C Act unless it appears on the list of bulk drug substances that may be used in compounding established by FDA." BPC-157 does not appear on that affirmative list.

This federal activity does not make BPC-157 possession a crime in Ohio, but it does mean that the window for any legitimate clinical compounding pathway has narrowed since 2023.

Ohio State Board of Pharmacy: What the Regulations Say

The Ohio State Board of Pharmacy enforces pharmacy practice law under ORC Chapter 4729. Key provisions relevant to BPC-157 include the following.

Prescription Requirements Under ORC 4729.51

ORC 4729.51 requires that any drug dispensed in Ohio be done so pursuant to a valid prescription for a drug that is legally authorizable to prescribe [6]. Because BPC-157 is not an approved drug, no valid prescription for it can be written under Ohio law. A licensed Ohio physician who writes a prescription for BPC-157 with intent to direct a patient to a compounding pharmacy could face professional licensing scrutiny from the State Medical Board of Ohio under ORC Chapter 4731.

No Ohio Medical Practice Act Exemption

Ohio's Medical Practice Act does not create a peptide research exemption. Physicians may investigate unapproved therapies under an FDA Investigational New Drug (IND) application, but that pathway requires formal trial registration, IRB oversight, and FDA authorization, not a simple telehealth visit [14].

What About Clinical Trials?

As of mid-2025, ClinicalTrials.gov lists a small number of studies examining BPC-157 or its derivatives, primarily outside the United States. No phase II or phase III registered human trial of BPC-157 is actively recruiting in Ohio or at Ohio-based academic medical centers. Participation in a legitimate clinical trial would be the only legal pathway by which an Ohio resident could receive BPC-157 under medical supervision in the United States.

Patients interested in this path can search the ClinicalTrials.gov registry directly [15]. Any trial recruiting in Ohio for BPC-157 would appear there with contact information.

A Practical Legal and Safety Summary for Ohio Residents

The situation can be condensed into four plain points.

First, BPC-157 is not a scheduled controlled substance. Personal possession is not a criminal offense under Ohio or federal law.

Second, no Ohio pharmacy can legally compound and dispense BPC-157 for patient use. The FDA's 503A framework blocks it.

Third, any telehealth platform claiming to prescribe BPC-157 in Ohio is operating in a legally questionable space. The prescription has no authorized drug to point to.

Fourth, purchasing from unregulated online vendors is legal for personal research purposes in a technical sense, but the safety risks are substantial and the products carry no quality guarantees.

Ohio residents who want access to peptide therapies for clinical conditions should discuss FDA-approved alternatives with a board-certified physician. For wound healing indications, FDA-approved options include becaplermin (Regranex) gel [16]. For gastrointestinal conditions, a gastroenterologist can discuss evidence-based treatments that have completed regulatory review.

Could the Legal Status Change?

Possibly. The FDA's 503A bulk substances nomination process is open. If a sponsor submits sufficient clinical safety and efficacy data for BPC-157, the FDA could move it from Category 2 to Category 1 and eventually to the affirmative bulks list. A completed U.S. IND application and successful phase II human trial would be the minimum threshold to trigger that review.

Given that no U.S. IND for BPC-157 with publicly visible phase II data exists as of July 2025, any regulatory change is likely years away. Ohio's legal field for BPC-157 reflects the current federal posture and will not change at the state level until the federal framework shifts.

Patients and clinicians monitoring this space should track the FDA's 503A bulks list directly, which is updated as the agency completes reviews [4].